3-(Iodoacetamido)-benzoylurea: A novel cancericidal tubulin ligand that inhibits microtubule polymerization, phosphorylates bcl-2, and induces apoptosis in tumor cells

Jian Dong Jiang, Ashley S. Davis, Kim Middleton, Yi He Ling, Roman Perez-Soler, James F. Holland, J. George Bekesi

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

3-(Iodoacetamido)-benzoylurea (3-IAABU) is a newly synthesized anti- tubulin compound with a molecular weight of 347. 3-IAABU exhibited anticancer activity in a variety of tumor cell lines with ID90 in the range of 0.015- 0.29 μM for leukemic cells and 0.06-0.92 μM for solid tumors. Higher selectivity against malignant cells was observed with 3-IAABU than that with vinblastine and paclitaxel. It inhibits microtubule assembly in tubulin systems either with or without microtubule-associated proteins (ID50 was 0.1 μM and 1.2 μM, respectively) and microtubule depolymerization was not affected, indicating an inhibition of polymerization by binding of 3-IAABU to the heterodimeric subunit of tubulin. 3-IAABU was shown to inhibit the binding of colchicine, a subunit binding compound, but did not inhibit binding of vinblastine and guanosine 5'-triphosphate/guanosine 5'- diphosphate, indicating that colchicine site corresponds to the site that 3- IAABU locates. Tumor cells treated with 3-IAABU showed scattered chromosomes in metaphase. Normal microtubule architecture or spindle apparatus was absent in these cells; instead, punctuated aggregates of tubulin were found by an immunofluorescent staining. Cell cycle analyses showed an accumulation of tumor cells at M phase after a 4-h treatment with 3-IAABU. The phosphorylated bcl-2 representative of an inactivated form of the oncoprotein was found in the cells 12 h after treatment with 3-IAABU. These cells progressed to apoptosis within 16 h. As a new tubulin ligand, 3-IAABU could be a promising agent in cancer chemotherapy.

Original languageEnglish (US)
Pages (from-to)5389-5395
Number of pages7
JournalCancer Research
Volume58
Issue number23
StatePublished - Dec 1 1998
Externally publishedYes

Fingerprint

Tubulin
Microtubules
Polymerization
Apoptosis
Ligands
Neoplasms
Vinblastine
Colchicine
Spindle Apparatus
Microtubule-Associated Proteins
Guanosine
Diphosphates
Oncogene Proteins
Metaphase
Paclitaxel
Guanosine Triphosphate
Tumor Cell Line
Cell Division
Antineoplastic Agents
Cell Cycle

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

3-(Iodoacetamido)-benzoylurea : A novel cancericidal tubulin ligand that inhibits microtubule polymerization, phosphorylates bcl-2, and induces apoptosis in tumor cells. / Jiang, Jian Dong; Davis, Ashley S.; Middleton, Kim; Ling, Yi He; Perez-Soler, Roman; Holland, James F.; Bekesi, J. George.

In: Cancer Research, Vol. 58, No. 23, 01.12.1998, p. 5389-5395.

Research output: Contribution to journalArticle

Jiang, Jian Dong ; Davis, Ashley S. ; Middleton, Kim ; Ling, Yi He ; Perez-Soler, Roman ; Holland, James F. ; Bekesi, J. George. / 3-(Iodoacetamido)-benzoylurea : A novel cancericidal tubulin ligand that inhibits microtubule polymerization, phosphorylates bcl-2, and induces apoptosis in tumor cells. In: Cancer Research. 1998 ; Vol. 58, No. 23. pp. 5389-5395.
@article{168a293d1f244cb28244c5f68c534e64,
title = "3-(Iodoacetamido)-benzoylurea: A novel cancericidal tubulin ligand that inhibits microtubule polymerization, phosphorylates bcl-2, and induces apoptosis in tumor cells",
abstract = "3-(Iodoacetamido)-benzoylurea (3-IAABU) is a newly synthesized anti- tubulin compound with a molecular weight of 347. 3-IAABU exhibited anticancer activity in a variety of tumor cell lines with ID90 in the range of 0.015- 0.29 μM for leukemic cells and 0.06-0.92 μM for solid tumors. Higher selectivity against malignant cells was observed with 3-IAABU than that with vinblastine and paclitaxel. It inhibits microtubule assembly in tubulin systems either with or without microtubule-associated proteins (ID50 was 0.1 μM and 1.2 μM, respectively) and microtubule depolymerization was not affected, indicating an inhibition of polymerization by binding of 3-IAABU to the heterodimeric subunit of tubulin. 3-IAABU was shown to inhibit the binding of colchicine, a subunit binding compound, but did not inhibit binding of vinblastine and guanosine 5'-triphosphate/guanosine 5'- diphosphate, indicating that colchicine site corresponds to the site that 3- IAABU locates. Tumor cells treated with 3-IAABU showed scattered chromosomes in metaphase. Normal microtubule architecture or spindle apparatus was absent in these cells; instead, punctuated aggregates of tubulin were found by an immunofluorescent staining. Cell cycle analyses showed an accumulation of tumor cells at M phase after a 4-h treatment with 3-IAABU. The phosphorylated bcl-2 representative of an inactivated form of the oncoprotein was found in the cells 12 h after treatment with 3-IAABU. These cells progressed to apoptosis within 16 h. As a new tubulin ligand, 3-IAABU could be a promising agent in cancer chemotherapy.",
author = "Jiang, {Jian Dong} and Davis, {Ashley S.} and Kim Middleton and Ling, {Yi He} and Roman Perez-Soler and Holland, {James F.} and Bekesi, {J. George}",
year = "1998",
month = "12",
day = "1",
language = "English (US)",
volume = "58",
pages = "5389--5395",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - 3-(Iodoacetamido)-benzoylurea

T2 - A novel cancericidal tubulin ligand that inhibits microtubule polymerization, phosphorylates bcl-2, and induces apoptosis in tumor cells

AU - Jiang, Jian Dong

AU - Davis, Ashley S.

AU - Middleton, Kim

AU - Ling, Yi He

AU - Perez-Soler, Roman

AU - Holland, James F.

AU - Bekesi, J. George

PY - 1998/12/1

Y1 - 1998/12/1

N2 - 3-(Iodoacetamido)-benzoylurea (3-IAABU) is a newly synthesized anti- tubulin compound with a molecular weight of 347. 3-IAABU exhibited anticancer activity in a variety of tumor cell lines with ID90 in the range of 0.015- 0.29 μM for leukemic cells and 0.06-0.92 μM for solid tumors. Higher selectivity against malignant cells was observed with 3-IAABU than that with vinblastine and paclitaxel. It inhibits microtubule assembly in tubulin systems either with or without microtubule-associated proteins (ID50 was 0.1 μM and 1.2 μM, respectively) and microtubule depolymerization was not affected, indicating an inhibition of polymerization by binding of 3-IAABU to the heterodimeric subunit of tubulin. 3-IAABU was shown to inhibit the binding of colchicine, a subunit binding compound, but did not inhibit binding of vinblastine and guanosine 5'-triphosphate/guanosine 5'- diphosphate, indicating that colchicine site corresponds to the site that 3- IAABU locates. Tumor cells treated with 3-IAABU showed scattered chromosomes in metaphase. Normal microtubule architecture or spindle apparatus was absent in these cells; instead, punctuated aggregates of tubulin were found by an immunofluorescent staining. Cell cycle analyses showed an accumulation of tumor cells at M phase after a 4-h treatment with 3-IAABU. The phosphorylated bcl-2 representative of an inactivated form of the oncoprotein was found in the cells 12 h after treatment with 3-IAABU. These cells progressed to apoptosis within 16 h. As a new tubulin ligand, 3-IAABU could be a promising agent in cancer chemotherapy.

AB - 3-(Iodoacetamido)-benzoylurea (3-IAABU) is a newly synthesized anti- tubulin compound with a molecular weight of 347. 3-IAABU exhibited anticancer activity in a variety of tumor cell lines with ID90 in the range of 0.015- 0.29 μM for leukemic cells and 0.06-0.92 μM for solid tumors. Higher selectivity against malignant cells was observed with 3-IAABU than that with vinblastine and paclitaxel. It inhibits microtubule assembly in tubulin systems either with or without microtubule-associated proteins (ID50 was 0.1 μM and 1.2 μM, respectively) and microtubule depolymerization was not affected, indicating an inhibition of polymerization by binding of 3-IAABU to the heterodimeric subunit of tubulin. 3-IAABU was shown to inhibit the binding of colchicine, a subunit binding compound, but did not inhibit binding of vinblastine and guanosine 5'-triphosphate/guanosine 5'- diphosphate, indicating that colchicine site corresponds to the site that 3- IAABU locates. Tumor cells treated with 3-IAABU showed scattered chromosomes in metaphase. Normal microtubule architecture or spindle apparatus was absent in these cells; instead, punctuated aggregates of tubulin were found by an immunofluorescent staining. Cell cycle analyses showed an accumulation of tumor cells at M phase after a 4-h treatment with 3-IAABU. The phosphorylated bcl-2 representative of an inactivated form of the oncoprotein was found in the cells 12 h after treatment with 3-IAABU. These cells progressed to apoptosis within 16 h. As a new tubulin ligand, 3-IAABU could be a promising agent in cancer chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0032403865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032403865&partnerID=8YFLogxK

M3 - Article

C2 - 9850070

AN - SCOPUS:0032403865

VL - 58

SP - 5389

EP - 5395

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 23

ER -